A week af­ter up­dat­ing their S-1 in search of at least $115 mil­lion on the hot biotech IPO mar­ket, Po­sei­da Ther­a­peu­tics says it’s al­so raised a fresh ven­ture round — a lit­tle more than a year af­ter its last.

The first time around, af­ter Po­sei­da de­layed its IPO dur­ing a gov­ern­ment shut­down, the biotech re­port­ed a $150 mil­lion C round. This time around, it’s adding $110 mil­lion more from Fi­deli­ty Man­age­ment Re­search Com­pa­ny and oth­ers.

There’s no word in the biotech’s state­ment on No­var­tis, which bought up half of the eq­ui­ty for the Se­ries C cash with a $75 mil­lion in­vest­ment.

Ac­cord­ing to the SEC fil­ing, No­var­tis — which field­ed the first, some­what trou­bled CAR-T — owns 14.9% of the com­pa­ny, with Ma­lin in for 23.2%, though those num­bers may have changed now.

The big ben­e­fi­cia­ry is CEO Er­ic Os­tertag, who con­trols 12.6 mil­lion shares — 25.4% — through var­i­ous fam­i­ly trusts.

Po­sei­da’s big idea in­volves the use of a non-vi­ral DNA tech that they say can be used to gath­er a big­ger con­cen­tra­tion of stem cell mem­o­ry T cells that can avoid the ex­haus­tion that lim­its the ef­fi­ca­cy of the pi­o­neers — a cen­tral theme in cell ther­a­py 2.0.

Os­tertag picked up his PhD in mol­e­c­u­lar bi­ol­o­gy at Penn and went on to a ca­reer that in­clud­ed a va­ri­ety of biotech star­tups.

As biotechs look to get clinical studies back on track amid the pandemic, Medable returned to the venture well for the second time this year, bagging a $91 million Series C to build out its virtual trial platform.

The software provider recently launched three new apps for decentralizing clinical trials, and saw a 500% revenue spike this year. And it isn’t alone. Back in August, Science 37 secured a $40 million round for its virtual trial tech, with support from Novartis, Sanofi Ventures and Amgen. Patients and researchers are taking a liking to the online approach, suggesting regulators could allow it to become a new normal even after the pandemic is over.

The first time San Diego biotech Ambrx tried to go public in 2014, they failed and the company’s board switched to a radically different strategy: They sold themselves for an undisclosed amount to a syndicate of Chinese investors and pharma companies.

Now, after 5 quiet years, that syndicate has raised a mountain of cash and indicated they’ll soon make another bid to go public.

Earlier this month, Ambrx raised $200 million in what they billed as a crossover round financed by Fidelity, BlackRock, Cormorant Asset Management, HBM Healthcare Investments, Invus, Adage Capital Partners and Suvretta Capital Management. It’s the largest amount they’ve ever raised and, according to Crunchbase figures, more than doubles the total amount of VC capital collected since their launch 17 years ago.

Just to complete the last leg of a running story I’ve been tracking for a few weeks, Olema $OLMA has come through its IPO from the Thursday night pricing at $19 a share with a market cap just north of $2 billion.

That leaves newly-named CEO Sean Bohen holding a batch of 1,110,896 shares with a strike price of $4.82. As of Tuesday morning, the stock is now trading at $53.40, giving him a portfolio value of $53.4 million. Not bad for someone who was hired in September.

Catamaran Bio’s founding members decided to jump into the CAR-NK game last December over drinks at a trendy bar in Boston.

They were sitting around a table, discussing an MD Anderson study which provided some of the first clinical proof that natural killer (NK) cells can be reengineered to attack tumors, much like CAR-T therapies. It was a “long and lively” discussion, COO Mark Boshar recalls. And by the time it was over, they had a starting point to launch a company.